Cantargia AB: Cantargia: ASCO 2022 presentation strengthens positive phase IIa interim results for nadunolimab in NSCLC
STOCKHOLM, May 26, 2022 /PRNewswire/ -- Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported updated interim results for non-small cell lung cancer (NSCLC) patients treated with